WHO, WHAT? The new vaccine trial results show 70% efficacy against Lyme disease.
Pfizer and Valneva have announced that their clinical trials for a potential Lyme disease vaccination demonstrated an overall effectiveness of approximately seventy percent in the latest phase (Ladepeche.fr). While some media outlets describe these findings as mitigated or mixed, both companies remain confident about the vaccine's long-term prospects despite not yet achieving perfect efficacy rates.
Key Points
-
1Pfizer and Valneva's vaccine for the disease of Lymes has shown 70% efficacy in clinical trials.
-
2The results were described as mitigated, though Pfizer remains confident about its potential despite this outcome.
Developments
Perspectives
The vaccine shows 70% efficacy in the clinical trial phase.
— [Mar 24, 16:13] Maladie de Lyme : le vaccin Pfizer-Valneva montre 70 % d'efficacité en phase dessai (Ladepeche.fr)The results of Valneva and Pfizer's vaccine against Lyme disease have disappointed the market.
— [Mar 23, 16:22] Les re´sultats du vaccin contre Lyme de Valnava et Pfizer dçoivent les marche`s (Lefigaro.fr)(No distinct perspective available from this source; it reports the same fact as other sources without adding a unique viewpoint).
— [Mar 23, 15:19] Pfizer ve Valneva'nın Lyme aşısı klinik denemede yüzde 70 etkili çıktı (Tr.euronews.com)(No distinct perspective available from this source; it reports the same fact as other sources without adding a unique viewpoint).
— [Mar 23, 15:19] Pfizer–Valneva Lyme-ko elleni vakcina ja 70%-os hatekonysa got mutat a klinikai proban (Hu.euronews.com)(No distinct perspective available from this source; it reports the same fact as other sources without adding a unique viewpoint).
— [Mar 23, 14:42] Maladie de Lyme : Pfizer ' confiant dans le potentiel d'un vaccin' à l'étude malgre des résultats mitigés (Sudouest.fr)